Longwood Valley MedTech Debuts ROPA6 'Six-in-One' AI Orthopedic Surgical Robot Platform at 20th China Hospital Presidents Annual Conference

XIAMEN, China — On a June evening in 2026, as hospital administrators and health-policy experts gathered on the southern coast for what organizers called a "20-year appointment," a relatively young medical-device company walked onto the exhibition floor with a claim that could reshape how orthopedic surgery is practiced worldwide.

Longwood Valley MedTech — known in China as Changmugu — brought its ROPA6 artificial-intelligence surgical robot to the 20th China Hospital Presidents Annual Conference, a flagship industry event themed "Crossing a New Cycle." The machine, the company says, is the world's first AI-powered orthopedic robot platform registered to perform six distinct surgical procedures from a single integrated system.

That claim matters. For years, orthopedic surgical robots have been built around a single procedure — a hip replacement system, say, or a knee-specific device. Hospitals that wanted robotic assistance across multiple orthopedic specialties had to buy multiple machines, train staff on each, and maintain separate workflows. The result: high cost, low utilization, and slow adoption, especially at smaller hospitals.

ROPA6 is designed to change that math. According to Longwood Valley, the system covers hip replacement, total knee replacement, unicompartmental knee replacement, spinal surgery, trauma surgery, and sports-medicine procedures — all from one robotic platform. The company says it uses sub-millimeter-level precision, a high-degree-of-freedom robotic arm, and AI deep-learning algorithms fused with advanced robot-control software on a single intelligent architecture.

A Platform, Not a Point Solution

The difference between ROPA6 and earlier orthopedic robots is not just feature count — it is a shift in how the industry thinks about surgical automation. Traditional machines offer "single-procedure assistance." ROPA6, Longwood Valley argues, represents "full-scenario platform leadership," a phrase that captures the company's ambition to move orthopedic robotics from niche tools to comprehensive operating-room infrastructure.

The company says ROPA6 is the first AI-integrated whole-orthopedic surgical robot platform to complete regulatory registration anywhere in the world. That registration covers the full six-procedure suite — hip, knee, unicompartmental knee, spine, trauma, and sports medicine — under a single product system, a first for the field.

The Team Behind the Robot

Longwood Valley MedTech, formally Beijing Longwood Valley Medical Technology Co., Ltd., is a national high-tech enterprise and a government-designated "little giant" in China's specialized and innovative company program. Its core research team comes from Harvard University, Stanford University, Tsinghua University, and Peking University, according to the company.

The company says it holds more than 300 domestic and international patents and software copyrights. It has completed seven rounds of financing through a Series B+ stage, with backing from investors including IDG Capital, CDH Investments, CICC Capital, Lenovo Capital, Lenovo Star, Yuanhe Capital, ZGC Development Group, Huajin Capital, FreeS Fund, and Youyin Xinneng.

A Conference Focused on Health-Care's Next Chapter

The 20th China Hospital Presidents Annual Conference, held June 5–6, 2026 in Xiamen, drew hospital leaders, academicians, and industry executives from across China. The main forum, themed "Anchoring the Health-First Strategy, Reconstructing Hospital Governance," focused on how public hospitals should adapt to payment reform, digital transformation, and population aging.

Ji Xunming, an academician of the Chinese Academy of Engineering and president of the Chinese Academy of Medical Sciences and Peking Union Medical College, said in his keynote that the health-care system must move away from a focus on treatment volume alone and toward a full-cycle service model centered on population health. Zhang Zhihui, executive president of China Hospital President magazine, said the era of competing on bed counts and outpatient visits is ending — the new metrics, he said, are quality, safety, efficiency, and patient satisfaction.

What Comes Next

Longwood Valley says it will continue developing AI and orthopedic-robotics technology, refining digital solutions that fit Chinese clinical settings and hospitals at every level. The company plans to deepen collaboration between clinicians and engineers, build more platforms for academic exchange and talent development, and push intelligent orthopedic tools into broader use.

Whether a single robot platform can truly replace a suite of specialized machines across six surgical disciplines will depend on clinical outcomes, regulatory acceptance, and hospital adoption patterns in the years ahead. For now, Longwood Valley has planted a flag: one system, six procedures, and a bet that the future of orthopedic surgery looks less like a collection of tools and more like a single intelligent machine.